| P50 | author | Espen Molden | Q43075786 |
| P2093 | author name string | Ragnhild Birkeland Waade | |
| | Tore Haslemo | |
| | Maren Hoff | |
| P2860 | cites work | Plasma concentrations of risperidone and 9-hydroxyrisperidone during combined treatment with paroxetine | Q43612961 |
| | Development of parkinsonian symptoms after discontinuation of carbamazepine in patients concurrently treated with risperidone: two case reports | Q43860867 |
| | Risperidone and 9-hydroxyrisperidone concentrations are not dependent on age or creatinine clearance among elderly subjects | Q44040865 |
| | Inhibition of risperidone metabolism by fluoxetine in patients with schizophrenia: a clinically relevant pharmacokinetic drug interaction | Q44097688 |
| | The brain entry of risperidone and 9-hydroxyrisperidone is greatly limited by P-glycoprotein | Q45245896 |
| | Management of agitation, aggression, and psychosis associated with dementia: a pooled analysis including three randomized, placebo-controlled double-blind trials in nursing home residents treated with risperidone | Q46515735 |
| | Influence of age and gender on risperidone plasma concentrations | Q46570350 |
| | P-glycoprotein interaction with risperidone and 9-OH-risperidone studied in vitro, in knock-out mice and in drug-drug interaction experiments | Q46666362 |
| | Serum concentrations of venlafaxine and its metabolites O-desmethylvenlafaxine and N-desmethylvenlafaxine in heterozygous carriers of the CYP2D6*3, *4 or *5 allele | Q46795534 |
| | Risperidone for psychosis of Alzheimer's disease and mixed dementia: results of a double-blind, placebo-controlled trial | Q46825630 |
| | Regional brain distribution of risperidone and its active metabolite 9-hydroxy-risperidone in the rat. | Q48186501 |
| | Blood-brain barrier P-glycoprotein function in Alzheimer's disease. | Q50778486 |
| | Predicting plasma concentration of risperidone associated with dosage change: a population pharmacokinetic study. | Q51412208 |
| | Influence of age, renal and liver impairment on the pharmacokinetics of risperidone in man. | Q51584263 |
| | A study of genetic (CYP2D6 and ABCB1) and environmental (drug inhibitors and inducers) variables that may influence plasma risperidone levels. | Q51751457 |
| | Mortality in elderly dementia patients treated with risperidone. | Q53282746 |
| | Polymorphisms in CYP2D6 have a greater effect on variability of risperidone pharmacokinetics than gender | Q57211998 |
| | Cytochrome P450 2D6 genotype and steady state plasma levels of risperidone and 9-hydroxyrisperidone | Q28368894 |
| | Risperidone and total 9-hydroxyrisperidone in relation to prescribed dose and other factors: data from a therapeutic drug monitoring service, 2002-2010. | Q34262574 |
| | Reversible coma caused by risperidone-ritonavir interaction. | Q34528565 |
| | Adverse drug reactions in special populations - the elderly | Q36125513 |
| | P-glycoprotein function at the blood-brain barrier: effects of age and gender | Q36382013 |
| | The complexity of active metabolites in therapeutic drug monitoring of psychotropic drugs | Q36548457 |
| | Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I. | Q37611786 |
| | The pharmacokinetics of paliperidone versus risperidone | Q37684643 |
| | AGNP Consensus Guidelines for Therapeutic Drug Monitoring in Psychiatry: Update 2011. | Q37942066 |
| | Clinically relevant interactions between newer antidepressants and second-generation antipsychotics | Q38185057 |
| | The impact of P-glycoprotein on the disposition of drugs targeted for indications of the central nervous system: evaluation using the MDR1A/1B knockout mouse model | Q38448723 |
| | Genetics-Based Population Pharmacokinetics and Pharmacodynamics of Risperidone in a Psychiatric Cohort | Q40780592 |
| | Therapeutic Drug Monitoring of Selective Serotonin Reuptake Inhibitors in Elderly Patients | Q41614367 |
| | Effects of CYP2D6 genotype on the pharmacokinetics, pharmacodynamics, and safety of risperidone in healthy volunteers | Q42918749 |
| P433 | issue | 5 | |
| P921 | main subject | risperidone | Q412443 |
| P304 | page(s) | 470-475 | |
| P577 | publication date | 2016-05-04 | |
| P1433 | published in | Basic and Clinical Pharmacology and Toxicology | Q15724438 |
| P1476 | title | Impact of Ageing on Serum Concentrations of Risperidone and Its Active Metabolite in Patients with Known CYP2D6 Genotype | |
| P478 | volume | 119 | |